Document Detail


Conventional treatment of hypercalcemia of malignancy.
MedLine Citation:
PMID:  11757206     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Treatment of hypercalcemia of malignancy (HCM) is briefly reviewed, available treatments are compared, and treatment guidelines are presented. The most effective strategy is treatment of the underlying malignancy. For patients who have a poor prognosis and no viable treatment options, the most humane course may be no treatment at all since encephalopathy will cloud their consciousness. Patients with mild hypercalcemia (corrected serum calcium concentration < 12 mg/dL) may respond to oral hydration, salt restriction, and ambulation, which encourage the normal bone remodeling process. Patients with moderate (corrected serum calcium concentration 12.0-13.5 mg/dL) to severe (> 13.5 mg/dL) hypercalcemia may require rehydration with 0.9% sodium chloride injection. Furosemide may be indicated to counteract fluid overload from rehydration measures or in patients at risk of developing congestive heart failure. For patients with renal failure not caused by dehydration, dialysis with a calcium-free or low-calcium solution is the treatment of choice. The calciuric effect of rehydration lasts only two to three days, and antiresorptive therapy is indicated for patients who require a longer duration of effect. Calcitonin is useful if a rapid decrease in serum calcium is necessary, but tachyphylaxis limits its use. Corticosteroids should be used only in patients with tumors that produce 1,25-dihydroxycholecalciferol. The use of plicamycin is limited because of adverse effects. Before the availability of zolendronic acid, pamidronate disodium was the treatment of choice, because of its longer duration of action than etidronate disodium and potential safety advantages. Zolendronic acid (discussed elsewhere in this supplement) is likely to supercede pamidronate disodium as the drug of choice for HCM, but the presence of symptoms, the rate of rise in serum calcium concentration, and the overall status of the patient are important considerations in selecting therapy.
Authors:
T G Davidson
Related Documents :
11742326 - Increased cardiovascular mortality and normalized serum calcium in patients with mild h...
20424476 - Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular...
18056506 - Crowned dens syndrome.
9724076 - [11c]methionine positron emission tomography for patients with persistent or recurrent ...
7656736 - Simultaneous dynamic proctography and peritoneography for pelvic floor disorders.
22920946 - Copper levels in patients with hematological malignancies.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  58 Suppl 3     ISSN:  1079-2082     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2001 Nov 
Date Detail:
Created Date:  2001-12-06     Completed Date:  2002-02-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S8-15     Citation Subset:  IM    
Affiliation:
Clinical Pharmacy Associates, Inc., 305 W. Country Drive, Duluth, GA 30097, USA. tdavidson@oncrx.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Calcitonin / therapeutic use
Clinical Protocols
Diphosphonates / therapeutic use
Drug Costs
Fluid Therapy
Gallium / therapeutic use
Humans
Hydrocortisone / therapeutic use
Hypercalcemia / drug therapy,  etiology,  therapy*
Imidazoles / therapeutic use
Neoplasms / complications*,  therapy
Nucleic Acid Synthesis Inhibitors / therapeutic use
Plicamycin / therapeutic use
Prednisone / therapeutic use
Rehydration Solutions / therapeutic use
Chemical
Reg. No./Substance:
0/Diphosphonates; 0/Imidazoles; 0/Nucleic Acid Synthesis Inhibitors; 0/Rehydration Solutions; 118072-93-8/zoledronic acid; 13494-90-1/gallium nitrate; 18378-89-7/Plicamycin; 50-23-7/Hydrocortisone; 53-03-2/Prednisone; 7440-55-3/Gallium; 9007-12-9/Calcitonin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Overview of hypercalcemia of malignancy.
Next Document:  The role of sodium in prevention and treatment of essential hypertension